Lifecore Biomedical, Inc. (LFCR) stock forecast & analysis
6.52
NasdaqGS · USD
Up: +2.32, +55.2%
1 analysis
- Open
- 6.52
- Previous close
- 4.20
- Day range
- 6.40 – 6.65
- 52-week range
- 3.63 – 8.98
- Volume (shares)
- 4.00M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 37.91M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- 1.09
- Market cap
- 247.15M
Market Scanner’s AI analysis of Lifecore Biomedical, Inc. (LFCR), updated September 2026: Lifecore Biomedical (LFCR) acquisition by Webster Equity Partners and mixed analyst sentiment dominate recent coverage.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Lifecore Biomedical, Inc. (LFCR) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Lifecore Biomedical (LFCR) acquisition by Webster Equity Partners and mixed analyst sentiment dominate recent coverage.
Recent analyses for LFCR covered a pending acquisition by Webster Equity Partners for up to $663 million. This news coincided with multiple analyst downgrades from Outperform/Buy ratings to Market Perform/Hold, signaling increased caution. Concurrently, technical indicators presented a strongly bullish outlook with price significantly outperforming moving averages and strong momentum readings.
LFCR news & sentiment
News reports detailed multiple analyst downgrades for Lifecore Biomedical, indicating increased caution. Concurrently, social media discussion showed a strongly bullish sentiment, driven by technical indicators and positive momentum readings.
LFCR technical picture
LFCR's price action showed significant outperformance relative to its moving averages, indicating a robust uptrend. Momentum indicators displayed extreme strength, with readings well into overbought territory, reinforcing upward price movement.
Fundamentals
LFCR reported fluctuating annual revenue with an increase in the most recent quarter. The company has experienced significant net losses and holds a negative profit margin and EPS. The market capitalization is $247,146,128.
Factors discussed — upside
- Technical indicators show a strongly bullish outlook with price outperforming moving averages.
- Momentum indicators (RSI, MFI, MACD) show extreme strength and buying pressure.
- Revenue showed an increase in the most recent reported quarter.
- Acquisition by Webster Equity Partners for up to $663 million.
Factors discussed — risks
- Multiple analyst downgrades from Outperform/Buy to Market Perform/Hold.
- Negative Profit Margin of -23.8% and negative EPS of -1.27.
- Significant net losses reported in recent fiscal years.
- Acquisition activity
- Analyst sentiment shifts
- Technical indicators
- Financial performance
Summary updated .
LFCR technical indicators
Common technical indicators for LFCR, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 4.51 | Price above |
| 10-day exponential moving average | 4.73 | Price above |
| Relative strength index (14-day) | 79.45 | Overbought |
| MACD line (12/26/9) | 0.1226 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 3.43 – 5.45 | Price above the upper band |
Analyses
Recent LFCR.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Lifecore Biomedical, Inc.?
- The bull case for LFCR is supported by a pending acquisition by Webster Equity Partners for up to $663 million, alongside strongly bullish technical indicators showing price outperformance and robust momentum. Recent revenue increases in the latest quarter also contribute to the positive outlook.
- What are the risks for Lifecore Biomedical, Inc.?
- Risks for LFCR include multiple recent analyst downgrades to Market Perform/Hold ratings, signaling increased caution, and persistent negative financial metrics such as a negative profit margin and EPS, alongside significant net losses in recent fiscal years.
- Is Lifecore Biomedical, Inc. bullish or bearish?
- Recent AI analyses of Lifecore Biomedical, Inc. examined factors on both sides. Discussed upside: The bull case for LFCR is supported by a pending acquisition by Webster Equity Partners for up to $663 million, alongside strongly bullish technical indicators showing price outperformance and robust momentum. Recent revenue increases in the latest quarter also contribute to the positive outlook. Discussed risks: Risks for LFCR include multiple recent analyst downgrades to Market Perform/Hold ratings, signaling increased caution, and persistent negative financial metrics such as a negative profit margin and EPS, alongside significant net losses in recent fiscal years. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Lifecore Biomedical, Inc.?
- News reports detailed multiple analyst downgrades for Lifecore Biomedical, indicating increased caution. Concurrently, social media discussion showed a strongly bullish sentiment, driven by technical indicators and positive momentum readings.
- How does Market Scanner analyse Lifecore Biomedical, Inc.?
- Every analysis of Lifecore Biomedical, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh LFCR.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.